Sertindole improves both the positive and negative symptoms of schizophrenia: Results of a phase III trial

International Journal of Psychiatry in Clinical Practice

Volumn 4, Issue 1, 2000, Pages 55-62

  Hale, Anthony ^a   Azorin, Jean Michel ^b   Kasper, Siegfried ^d   Maier, Wolfgang ^c   Syvälahti, Erkka ^d   Van Der Burght, Michael ^e   Sloth Nielsen, Mogens ^e   Wehnert, Allan ^e  

^a UNIVERSITY OF KENT   (United Kingdom)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d Dept Pharmacol Clin Pharmacol ^*

^e H LUNDBECK A S   (Denmark)

Author keywords

Negative symptoms; Phase III clinical trial; Positive symptoms; Schizophrenia; Sertindole

Indexed keywords

SERTINDOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT PLANNING;

EID: 0034039868     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500050518406     Document Type: Article

References (24)

1. Crow TJ (1985) The two-syndrome concept: origins and current status. Schizophr Bull 11: 471-78.
2. Skarsfeldt T, Perregaard J (1990) Sertindole, a new neuroleptic with extreme selectivity on AlO versus A9 dopamine neurones in rats. Eur J Phannacol 182: 613-14.
3. Metzler HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43: 587-604.
4. Jibson MD, Tandon R (1996) A summary of research findings on the new antipsychotic drugs. Essential Psychopharmacol 1: 27-37.
5. Zimbroff D, Kane JM, Tamminga CA et al (1997) Controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiatry 154: 782-91.
6. Arnt J (1998) How well do memory and learning relate to pharmacological profiles? Int J Psychiatr Clin Prac 2 (Suppl 2): S7-S14.
7. Gallhofer B (1998) Is cognition influenced by second generation antipsychotics? Int J Psychiatr Clin Prac 2 (suppl 2): S15-S18.
8. Tamminga CA, Buchanan RW, Gold JM (1998) The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 13 (suppl 3): S21-S26.
9. Van Putten T, Marder SR, Mintz J (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenics. Arch Gen Psychiatry 47: 754-58.
10. Rifkin A, Doddi S, Karajgi B et al (1991) Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48: 166-70.
11. Kay SR, Fisbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-76.
12. Simpson G, Angus JSW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 (suppl): 11-19.
13. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health and Human Services publication (ADM). 76-338: 534-35.
14. Van Putten T, Marder SR, Mintz J et al (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 149: 510-15.
15. Lindenmayer JP, Bernstein-Hyman R, Grochowski S (1994) A new five-factor model of schizophrenia. Psychiatr Q 65 (Winter): 299-322.
16. Jonckheere AR (1954) A distribution-free k-sample test against ordered alternative. Biometrika 41: 133-45.
17. Terpstra TJ (1992) The asymptotic normality and consistency of Kendall's test against trend, when ties are present in one ranking. Indagations Math 14: 327-33.
18. Hale AS, Azorin J-M, Maier W et al (1998) Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: results of a phase III trial. Int J Psychiatry Clin Pract 4: 47-54.
19. Hale AS (1993) Will new antipsychotics improve the treatment of schizophrenia? Br Med J 307: 749-50.
20. Möller HJ, Müller H (1997) Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. Eur Arch Psychiatry Clin Neurosci 247: 1-5.
21. Möller HJ (1998) Novel antipsychotics and negative symptoms. Int Clin Psychopharmacol 13 (suppl 3): S43-S47.
22. th, Nice, France.
23. th, Nice, France.
24. Van Kammen D, McEvoy J, Targum S et al (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berlin) 124: 168-75.